Who are we?

Ferring Research Institute (FRI) is the research arm and ideas incubator of Ferring Pharmaceuticals, a global biopharmaceutical company that employs over 6,000 people in 56 countries.
FRI brings together 80+ scientists, clinicians and technicians from across the world. Together, we work to progress Ferring’s early pipeline, supported by colleagues from our data analytics and strategy divisions, and our other global early research facilities in Denmark and Israel.
Everyone in our team is motivated by a passion for discovery. We combine our talents with world-class science to drive forward our R&D and scientific innovation efforts to deliver transformational new medicines for patients.

Ferring Research Institute

Ferring Research Institute, Inc. (FRI) is located in the heart of the biopharmaceutical community in San Diego, California. FRI was established in 1996 and you can read more about Ferring’s history here.

Our scientists here work on early drug development activities across our key therapeutic areas – from idea generation to clinical proof of concept.

They do this in close collaboration with our colleagues at two other Ferring research hubs in:

• Copenhagen, Denmark: This site, the International PharmaScience Center, houses our bioanalysis, discovery biotherapeutics and immunology laboratories. A center of excellence for immunology science innovation and idea generation throughout Ferring, it is the base for our clinical pharmacology and pharmacokinetics scientists and our site for screening of novel antibodies. Our teams of scientists across both sites work in close collaboration.

• Be’er Tuvia, Israel: This facility, Bio-Technology General (BTG), has pioneered the development and manufacture of human healthcare products derived from genetic engineering and biotechnology processes. It has a strong track record of developing and registering biopharmaceuticals.

Our focus

We’re driving innovation in several key therapy areas, including:

• Reproductive Medicine and Maternal Health
• Gastroenterology and the Microbiome
• Immunology

Investing in our future

A major investment program is underway at FRI, expanding and modernizing our research facilities. On completion in 2022, this will deliver a state-of-the-art environment for scientific discovery.

It will further improve the capability and reach of Ferring’s research, enabling it to bring groundbreaking science and more new medicines to the people who need them most.